EMERYVILLE, Calif.–(BUSINESS WIRE)—- $OABI #Antibody–OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates. “Our business momentum has continued with the recent addition of three new partners including another global pharma company. Despite macroeconomic conditions,…
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
